The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 2, 2011, Pages 389-398

  Na, Young Soon ^a   Jung, Kyung Ah ^a   Kim, Seung Mi ^a   Hong, Yong Sang ^b   Ryu, Min Hee ^b   Jang, Se Jin ^b   Moon, Dae Hyuk ^b   Cho, Dong Hyung ^a   Kim, Jin Cheon ^b   Lee, Jung Shin ^b   Kim, Tae Won ^b  

^a Asan Medical Center   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

18F FLT PET; Colon cancer; Histone deacetylase inhibitor; Irinotecan; PXD101

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BELINOSTAT; IRINOTECAN; THYMIDINE KINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL STRAIN HCT116; CELL STRAIN HT29; CELL VIABILITY; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MORNING DOSAGE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CAMPTOTHECIN; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG SYNERGISM; FEMALE; HCT116 CELLS; HISTONE DEACETYLASE INHIBITORS; HT29 CELLS; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, NUDE; PRODRUGS; RANDOM ALLOCATION; TOPOISOMERASE I INHIBITORS; TUMOR BURDEN; WHOLE BODY IMAGING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960912286     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1495-6     Document Type: Article

References (44)

1. A Jemal R Siegel E Ward Y Hao J Xu, et al. 2009 Cancer statistics, 2009 CA Cancer J Clin 59 225 249 19474385 10.3322/caac.20006
2. CH Kohne HJ Lenz 2009 Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer Oncologist 14 478 488 19411318 10.1634/theoncologist.2008-0202
3. J Weekes AK Lam S Sebesan YH Ho 2009 Irinotecan therapy and molecular targets in colorectal cancer: a systemic review World J Gastroenterol 15 3597 3602 19653336 10.3748/wjg.15.3597 1:CAS:528:DC%2BD1MXhtVSksrrM
4. BA Teicher 2008 Next generation topoisomerase I inhibitors: rationale and biomarker strategies Biochem Pharmacol 75 1262 1271 18061144 10.1016/j.bcp.2007.10.016 1:CAS:528:DC%2BD1cXislamtL8%3D (Pubitemid 351305209)
5. PA Marks WS Xu 2009 Histone deacetylase inhibitors: potential in cancer therapy J Cell Biochem 107 600 608 19459166 10.1002/jcb.22185 1:CAS:528:DC%2BD1MXosFOiurg%3D
6. MM Knupfer F Pulzer I Schindler P Hernaiz Driever H Knupfer, et al. 2001 Different effects of valproic acid on proliferation and migration of malignant glioma cells in vitro Anticancer Res 21 347 351 11299760 1:CAS:528: DC%2BD3MXivFCmsLY%3D
7. O Witt S Monkemeyer K Kanbach A Pekrun 2002 Induction of fetal hemoglobin synthesis by valproate: modulation of MAP kinase pathways Am J Hematol 71 45 46 12221674 10.1002/ajh.10161 1:CAS:528:DC%2BD38XnsVOhsb8%3D (Pubitemid 34988586)
8. PX Yuan LD Huang YM Jiang JS Gutkind HK Manji, et al. 2001 The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth J Biol Chem 276 31674 31683 11418608 10.1074/jbc.M104309200 1:CAS:528:DC%2BD3MXms1Smsro%3D
9. AJ Wilson DS Byun N Popova LB Murray K L'Italien, et al. 2006 Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer J Biol Chem 281 13548 13558 16533812 10.1074/jbc.M510023200 1:CAS:528:DC%2BD28Xkt1ymt7Y%3D (Pubitemid 43855268)
10. M Nakagawa Y Oda T Eguchi S Aishima T Yao, et al. 2007 Expression profile of class I histone deacetylases in human cancer tissues Oncol Rep 18 769 774 17786334 1:CAS:528:DC%2BD2sXhtFygu7vK
11. JM Mariadason 2008 HDACs and HDAC inhibitors in colon cancer Epigenetics 3 28 37 18326939 10.4161/epi.3.1.5736 (Pubitemid 351540961)
12. H Nian WH Bisson WM Dashwood JT Pinto RH Dashwood 2009 Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells Carcinogenesis 30 1416 1423 19528666 10.1093/carcin/bgp147 1:CAS:528:DC%2BD1MXpsVakt7s%3D
13. JJ Buggy ZA Cao KE Bass E Verner S Balasubramanian, et al. 2006 CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo Mol Cancer Ther 5 1309 1317 16731764 10.1158/1535-7163.MCT-05-0442 1:CAS:528:DC%2BD28XltVWms7Y%3D (Pubitemid 43881324)
14. W Fazzone PM Wilson MJ Labonte HJ Lenz RD Ladner 2009 Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells Int J Cancer 125 463 473 19384949 10.1002/ijc.24403 1:CAS:528:DC%2BD1MXms1alsr4%3D
15. JC Kim ES Shin CW Kim SA Roh DH Cho, et al. 2009 In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer Anticancer Res 29 3027 3034 19661311 1:CAS:528:DC%2BD1MXhtVeku7%2FK
16. HM Prince MJ Bishton SJ Harrison 2009 Clinical studies of histone deacetylase inhibitors Clin Cancer Res 15 3958 3969 19509172 10.1158/1078-0432.CCR-08-2785 1:CAS:528:DC%2BD1MXntlOis78%3D
17. L Stimson NB La Thangue 2009 Biomarkers for predicting clinical responses to HDAC inhibitors Cancer Lett 280 177 183 19362413 10.1016/j.canlet.2009.03. 016 1:CAS:528:DC%2BD1MXmsF2jt7o%3D
18. A Salskov VS Tammisetti J Grierson H Vesselle 2007 FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3′-deoxy-3′-[18F]fluorothymidine Semin Nucl Med 37 429 439 17920350 10.1053/j.semnuclmed.2007.08.001 (Pubitemid 47498262)
19. AF Shields JR Grierson BM Dohmen HJ Machulla JC Stayanoff, et al. 1998 Imaging proliferation in vivo with [F-18]FLT and positron emission tomography Nat Med 4 1334 1336 9809561 10.1038/3337 1:CAS:528:DyaK1cXntlaqsrk%3D (Pubitemid 28512118)
20. JS Rasey JR Grierson LW Wiens PD Kolb JL Schwartz 2002 Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells J Nucl Med 43 1210 1217 12215561 1:CAS:528:DC%2BD38Xns1elsrk%3D (Pubitemid 34988769)
21. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55 6382953 10.1016/0065-2571(84)90007-4 1:CAS:528: DyaL2cXktlaksLk%3D
22. TC Chou RJ Motzer Y Tong GJ Bosl 1994 Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design J Natl Cancer Inst 86 1517 1524 7932806 10.1093/jnci/86.20.1517 1:CAS:528:DyaK2cXmvFWru7w%3D (Pubitemid 24330215)
23. SJ Martin JA Eisenbarth U Wagner-Utermann W Mier M Henze, et al. 2002 A new precursor for the radiosynthesis of [18F]FLT Nucl Med Biol 29 263 273 11823132 10.1016/S0969-8051(01)00289-X 1:CAS:528:DC%2BD38XovFCmtw%3D%3D (Pubitemid 34127960)
24. JA Plumb PW Finn RJ Williams MJ Bandara MR Romero, et al. 2003 Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101 Mol Cancer Ther 2 721 728 12939461 1:CAS:528:DC%2BD3sXms1GktLo%3D
25. AB Niculescu 3rd X Chen M Smeets L Hengst C Prives, et al. 1998 Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication Mol Cell Biol 18 629 643 9418909 1:CAS:528: DyaK1cXjtFCqtA%3D%3D (Pubitemid 28021073)
26. R Rodriguez LT Hansen G Phear J Scorah M Spang-Thomsen, et al. 2008 Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+cells and tumors containing a mutation of MRE11 Clin Cancer Res 14 5476 5483 18765539 10.1158/1078-0432.CCR-08-0274 1:CAS:528:DC%2BD1cXhtVKmsbjL
27. Y Liu H Xing D Weng X Song X Qin, et al. 2009 Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer Cancer Lett 274 47 53 18929442 10.1016/j.canlet.2008.08.037 1:CAS:528:DC%2BD1cXhsFCmsLrF
28. Y Dai S Chen LB Kramer VL Funk P Dent, et al. 2008 Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells Clin Cancer Res 14 549 558 18223231 10.1158/1078-0432.CCR-07-1934 1:CAS:528:DC%2BD1cXhtVKhsLc%3D (Pubitemid 351226125)
29. J Leyton JP Alao M Da Costa AV Stavropoulou JR Latigo, et al. 2006 In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography Cancer Res 66 7621 7629 16885362 10.1158/0008-5472.CAN-05-3962 1:CAS:528:DC%2BD28XnsFyru74%3D (Pubitemid 44289219)
30. DM Voeller JL Grem Y Pommier K Paull CJ Allegra 2000 Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs Cancer Chemother Pharmacol 45 409 416 10803925 10.1007/s002800051010 1:CAS:528:DC%2BD3cXhvVSms70%3D (Pubitemid 30217166)
31. P Piacentini M Donadelli C Costanzo PS Moore M Palmieri, et al. 2006 Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation Virchows Arch 448 797 804 16568310 10.1007/s00428-006-0173-x 1:CAS:528:DC%2BD28XltFWksrw%3D (Pubitemid 43824437)
32. X Zhang M Yashiro J Ren K Hirakawa 2006 Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines Oncol Rep 16 563 568 16865256 1:CAS:528:DC%2BD28XptVagsL8%3D
33. DC Marchion E Bicaku AI Daud V Richon DM Sullivan, et al. 2004 Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid J Cell Biochem 92 223 237 15108350 10.1002/jcb.20045 1:CAS:528:DC%2BD2cXjvVaqs7c%3D
34. DC Marchion E Bicaku JG Turner AI Daud DM Sullivan, et al. 2005 Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta Clin Cancer Res 11 8467 8475 16322310 10.1158/1078-0432.CCR-05-1073 1:CAS:528:DC%2BD2MXht1KjsrbF (Pubitemid 41746962)
35. Fetterly GJ, Brady WE, LeVea CM, Litwin AM, Zagst PD, Prey JD, Tarquini M, Giardina MK, Iyer RV, Khushalani NI (2009) A phase I pharmacokinetic (PK) study of vorinostat in combination with irinotecan, 5-fluorouracil, and leucovorin in advanced upper gastrointestinal cancers. J Clin Oncol 27:15s (suppl; abstr e15540)
36. H Takemura VA Rao O Sordet T Furuta ZH Miao, et al. 2006 Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks J Biol Chem 281 30814 30823 16905549 10.1074/jbc.M603747200 1:CAS:528:DC%2BD28XhtVCrsLjL (Pubitemid 44582136)
37. KB Glaser 2007 HDAC inhibitors: clinical update and mechanism-based potential Biochem Pharmacol 74 659 671 17498667 10.1016/j.bcp.2007.04.007 1:CAS:528:DC%2BD2sXotlajsr8%3D (Pubitemid 47096639)
38. MJ LaBonte PM Wilson W Fazzone S Groshen HJ Lenz, et al. 2009 DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines BMC Med Genomics 2 67 19948057 10.1186/1755-8794-2-67
39. O Tredan CM Galmarini K Patel IF Tannock 2007 Drug resistance and the solid tumor microenvironment J Natl Cancer Inst 99 1441 1454 17895480 10.1093/jnci/djm135 1:CAS:528:DC%2BD2sXht1yltbrO
40. HW Jeon YM Lee 2010 Inhibition of histone deacetylase attenuates hypoxia-induced migration and invasion of cancer cells via the restoration of RECK expression Mol Cancer Ther 9 1361 1370 20442303 10.1158/1535-7163.MCT-09- 0717 1:CAS:528:DC%2BC3cXlslektL4%3D
41. J Shen C Hughes C Chao J Cai C Bartels, et al. 1987 Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells Proc Natl Acad Sci USA 84 3278 3282 3106964 10.1073/pnas.84.10.3278 1:CAS:528:DyaL2sXktFOns78%3D (Pubitemid 17085387)
42. LE Gerweck S Vijayappa S Kozin 2006 Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics Mol Cancer Ther 5 1275 1279 16731760 10.1158/1535-7163.MCT-06-0024 1:CAS:528:DC%2BD28XltVWmsrY%3D (Pubitemid 43881320)
43. N Raghunand X He R van Sluis B Mahoney B Baggett, et al. 1999 Enhancement of chemotherapy by manipulation of tumour pH Br J Cancer 80 1005 1011 10362108 10.1038/sj.bjc.6690455 1:CAS:528:DyaK1MXjvFSitbg%3D (Pubitemid 29233921)
44. A Mercalli V Sordi R Formicola M Dandrea S Beghelli, et al. 2007 A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer Br J Cancer 96 1358 1367 17426706 1:CAS:528:DC%2BD2sXkslyisr0%3D (Pubitemid 46685787)